Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints
Antibiotic resistance among elderly population
Reimbursement issues for antibiotics
HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152)
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144)
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act Issues related to Medicare reimbursement of antibiotics; H.R. 4187, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms
HR 3402 Protecting Access to Medicare Act of 2014  Public Law No: 113-93
In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs Issues related to antibiotics, breakpoints, and following bills
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs Implementation of the GAIN provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA)  PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742  the Antibiotic Development to Advance Patient Treatment Act of 2013
HR 4187  Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CUBIST PHARMACEUTICALS, INC.
65 Hayden Avenue, Lexington, MA, 02421, US
MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES